利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

59 条记录 (耗时 0.028 秒)

    METHOD AND APPARATUS FOR ELECTRICALLY STIMULATING THE NERVOUS SYSTEM TO IMPROVE VENTRICULAR DYSFUNCTION, HEART FAILURE, AND OTHER CARDIAC CONDITIONS
    42.
    发明申请
    METHOD AND APPARATUS FOR ELECTRICALLY STIMULATING THE NERVOUS SYSTEM TO IMPROVE VENTRICULAR DYSFUNCTION, HEART FAILURE, AND OTHER CARDIAC CONDITIONS 有权
    用于电刺激神经系统以改善心脏功能障碍，心脏衰竭和其他心脏病症的方法和装置

    公开(公告)号：US20100016919A1

    公开(公告)日：2010-01-21

    申请号：US12565910

    申请日：2009-09-24

    申请人： Michael R.S. Hill ,  Gary W. King ,  Thomas J. Mullen ,  Xiaohong Zhou

    发明人： Michael R.S. Hill ,  Gary W. King ,  Thomas J. Mullen ,  Xiaohong Zhou

    IPC分类号： A61N1/365

    CPC分类号： A61N1/36114 ,  A61N1/3627

    摘要： A method and apparatus are used to provide therapy to a patient experiencing ventricular dysfunction or heart failure. At least one electrode is located in a region associated with nervous tissue, such as nerve bundles T1-T4, in a patient's body. Electrical stimulation is applied to the at least one electrode to improve the cardiac efficiency of the patient's heart. One or more predetermined physiologic parameters of the patient are monitored, and the electrical stimulation is adjusted based on the one or more predetermined physiologic parameters.

    摘要翻译： 使用方法和装置为患有心室功能障碍或心力衰竭的患者提供治疗。 至少一个电极位于与患者体内的神经组织如神经束T1-T4相关联的区域中。 电刺激被施加到至少一个电极以改善患者心脏的心脏效率。 监测患者的一个或多个预定生理参数，并且基于一个或多个预定生理参数来调整电刺激。

    Methods and apparatus for the regulation of hormone release
    43.
    发明授权
    Methods and apparatus for the regulation of hormone release 有权
    用于调节激素释放的方法和装置

    公开(公告)号：US07650190B2

    公开(公告)日：2010-01-19

    申请号：US11751813

    申请日：2007-05-22

    申请人： Xiaohong Zhou ,  Thomas J. Mullen ,  Gary W. King ,  Michael R. S. Hill

    发明人： Xiaohong Zhou ,  Thomas J. Mullen ,  Gary W. King ,  Michael R. S. Hill

    IPC分类号： A61N1/00

    CPC分类号： A61N1/36071 ,  A61N1/205 ,  A61N1/36021

    摘要： A method and apparatus for delivering corrective therapy through hormone regulation is provided. Inhibition of sympathetic fibers by spinal cord stimulation is used to regulate the levels of hormones such as catecholamines, renin, and calcitonin gene-related peptide. The invention utilizes a closed or open loop feedback system in which physiological parameters such as the concentrations of hormones and sympathetic indicators such as heart rate and urine production are monitored and used to determine the appropriate level of neurostimulation. The site of electrical stimulation includes, but is not limited to, the spinal cord at levels T7-L2 and the associated neural fibers within a region of the T7-L2 dermatomes.

    摘要翻译： 提供了一种通过激素调节进行矫正治疗的方法和装置。 通过脊髓刺激抑制交感神经纤维用于调节激素水平，如儿茶酚胺，肾素和降钙素基因相关肽。 本发明利用封闭或开环反馈系统，其中监测诸如心率和尿液产生之间的激素和交感神经指标的生理参数，并用于确定适当的神经刺激水平。 电刺激部位包括但不限于在T7-L2皮层区域内的T7-L2级和相关神经纤维的脊髓。

    APPARATUS AND METHODS FOR AUTOMATIC ADJUSTMENT OF AV INTERVAL TO ENSURE DELIVERY OF CARDIAC RESYNCHRONIZATION THERAPY
    46.
    发明申请
    APPARATUS AND METHODS FOR AUTOMATIC ADJUSTMENT OF AV INTERVAL TO ENSURE DELIVERY OF CARDIAC RESYNCHRONIZATION THERAPY 审中-公开
    用于自动调整AV间隔以确保进行心脏再生治疗的装置和方法

    公开(公告)号：US20130013017A1

    公开(公告)日：2013-01-10

    申请号：US13610163

    申请日：2012-09-11

    申请人： Thomas J. Mullen ,  John E. Burnes ,  Aleksandre T. Sambelashvili

    发明人： Thomas J. Mullen ,  John E. Burnes ,  Aleksandre T. Sambelashvili

    IPC分类号： A61N1/365

    CPC分类号： A61N1/3627 ,  A61N1/3682 ,  A61N1/3684

    摘要： Methods and apparatus of left ventricular pacing including automated adjustment of a atrio-ventricular (AV) pacing delay interval and intrinsic AV nodal conduction testing. Thus, in the event that the AV conduction test reveals a physiologically acceptable intrinsic PR interval then storing the physiologically acceptable PR interval in a memory structure (e.g., a median P-R from one or more cardiac cycles) and delivering fusion pacing using a decremented value of the intrinsic PR interval.

    摘要翻译： 左心室起搏的方法和装置，包括自动调整心房（AV）起搏延迟间隔和固有AV节点传导测试。 因此，在AV传导测试揭示生理上可接受的固有PR间隔的情况下，然后将生理上可接受的PR间期存储在存储器结构中（例如，来自一个或多个心动周期的中值PR）并且使用递减值 内在PR间期。

    Mechanical function marker channel for cardiac monitoring and therapy control
    47.
    发明授权
    Mechanical function marker channel for cardiac monitoring and therapy control 有权
    用于心脏监测和治疗控制的机械功能标记通道

    公开(公告)号：US08340750B2

    公开(公告)日：2012-12-25

    申请号：US11780140

    申请日：2007-07-19

    申请人： Rajan Prakash ,  Sameh Sowelam ,  Thomas J. Mullen

    发明人： Rajan Prakash ,  Sameh Sowelam ,  Thomas J. Mullen

    IPC分类号： A61B5/00

    CPC分类号： A61B5/0031 ,  A61B5/0215 ,  A61B5/042 ,  A61B5/11 ,  A61B5/14546 ,  A61B5/1455 ,  A61B5/7239 ,  A61N1/36514 ,  A61N1/36564 ,  A61N1/36578

    摘要： The implantable medical device (IMD) system disclosed here utilizes one or more cardiac sensors that measure mechanical characteristics of the heart, such as left ventricular acceleration or right ventricular pressure. The raw sensor data is collected and processed by the IMD, which derives one or more mechanical event marker signals from features, traits, and characteristics of the sensor data waveforms. The mechanical event marker signals are wirelessly transmitted to an external monitor device for display.

    摘要翻译： 这里公开的可植入医疗装置（IMD）系统利用测量心脏的机械特征的一个或多个心脏传感器，例如左心室加速度或右心室压力。 原始传感器数据由IMD收集和处理，IMD从特征，特征和传感器数据波形的特性中导出一个或多个机械事件标记信号。 机械事件标记信号被无线传输到外部监视器装置进行显示。

    Fusion pacing interval determination
    49.
    发明授权
    Fusion pacing interval determination 有权
    融合起搏间隔测定

    公开(公告)号：US08204590B2

    公开(公告)日：2012-06-19

    申请号：US12363025

    申请日：2009-01-30

    申请人： Aleksandre T. Sambelashvili ,  Thomas J. Mullen ,  Berthold Stegemann

    发明人： Aleksandre T. Sambelashvili ,  Thomas J. Mullen ,  Berthold Stegemann

    IPC分类号： A61N1/365

    CPC分类号： A61N1/3627 ,  A61N1/36514 ,  A61N1/3684 ,  A61N1/3688

    摘要： Delivery of fusion pacing therapy to a later depolarizing ventricle (V2) of a heart of a patient may be timed based on the depolarization of the V2 during at least one prior cardiac cycle. In some examples, a V2 pacing pulse is delivered upon the expiration of a pacing interval that begins at detection of an atrial sense or pace event (AP/S). The pacing interval may be substantially equal to the duration of time between an AP/S and a V2 sensing event of at least one prior cardiac cycle decremented by an adjusted pre-excitation interval (PEI). In another example, the V2 pacing pulse is delivered at the expiration of a pacing interval that begins upon detection of a V2 sensing event of a prior cardiac cycle. The pacing interval may be substantially equal to a duration of time at least two subsequent V2 sensing events decremented by the adjusted PEI.

    摘要翻译： 将融合起搏治疗递送到患者心脏的后期去极化心室（V2）可以基于在至少一个在先的心动周期期间的V2的去极化来计时。 在一些示例中，在起搏间隔期满后，在起搏时间间隔期间，起搏脉搏是在心房感觉或步速事件（AP / S）的检测开始时发送的。 所述起搏间隔可以基本上等于在调整的预激励间隔（PEI）减小的至少一个先前心动周期的AP / S和V2感测事件之间的持续时间。 在另一示例中，V2起搏脉冲在起搏间隔的期满时被递送，起搏间隔开始于检测到先前的心动周期的V2感测事件。 起搏间隔可以基本上等于由调整后的PEI递减的至少两个后续V2感测事件的持续时间。